# Marco Siccardi

## List of Publications by Citations

| | | | |
|---|---|---|---|
| **126** papers | **2,816** citations | **31** h-index | **46** g-index |
| **131** ext. papers | **3,120** ext. citations | **5** avg, IF | **4.94** L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 126 | Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. *Aids*, **2010**, 24, 1064-6 | 3.5 | 103 |
| 125 | Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2010**, 878, 1455-65 | 3.2 | 100 |
| 124 | An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. *Therapeutic Drug Monitoring*, **2008**, 30, 662-9 | 3.2 | 99 |
| 123 | Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 2092-8 | 5.1 | 87 |
| 122 | New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2009**, 877, 1721-6 | 3.2 | 82 |
| 121 | HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2007**, 859, 234-40 | 3.2 | 77 |
| 120 | Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir. *Clinical Infectious Diseases*, **2008**, 47, 1222-5 | 11.6 | 73 |
| 119 | Optimizing nanomedicine pharmacokinetics using physiologically based pharmacokinetics modelling. *British Journal of Pharmacology*, **2014**, 171, 3963-79 | 8.6 | 67 |
| 118 | Development and validation of a simultaneous extraction procedure for HPLC-MS quantification of daptomycin, amikacin, gentamicin, and rifampicin in human plasma. *Analytical and Bioanalytical Chemistry*, **2010**, 396, 791-8 | 4.4 | 64 |
| 117 | Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 5242-50 | 5.9 | 63 |
| 116 | Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation. *Advanced Healthcare Materials*, **2014**, 3, 400-11 | 10.1 | 62 |
| 115 | HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. *Journal of Pharmaceutical and Biomedical Analysis*, **2010**, 52, 774-80 | 3.5 | 62 |
| 114 | Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV. *Clinical Pharmacokinetics*, **2015**, 54, 639-50 | 6.2 | 57 |
| 113 | A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. *Journal of Pharmaceutical and Biomedical Analysis*, **2011**, 54, 779-88 | 3.5 | 55 |
| 112 | Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 2976-8 | 5.9 | 53 |
| 111 | Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 879-87 | 5.9 | 51 |
| 110 | Divalent metals and pH alter raltegravir disposition in vitro. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 3020-6 | 5.9 | 46 |

| 109 | Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2006**, 835, 127-30 | 3.2 | 46 |
|---|---|---|---|
| 108 | Development, validation, and routine application of a high-performance liquid chromatography method coupled with a single mass detector for quantification of itraconazole, voriconazole, and posaconazole in human plasma. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 3408-13 | 5.9 | 45 |
| 107 | Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. *Clinical Pharmacokinetics*, **2013**, 52, 583-92 | 6.2 | 43 |
| 106 | Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals. *Journal of Antimicrobial Chemotherapy*, **2011**, 66, 1332-9 | 5.1 | 42 |
| 105 | Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. *Pharmacogenetics and Genomics*, **2010**, 20, 759-65 | 1.9 | 38 |
| 104 | Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. *Therapeutic Drug Monitoring*, **2012**, 34, 165-70 | 3.2 | 37 |
| 103 | Simultaneous quantification of linezolid, rifampicin, levofloxacin, and moxifloxacin in human plasma using high-performance liquid chromatography with UV. *Therapeutic Drug Monitoring*, **2009**, 31, 104-9 | 3.2 | 36 |
| 102 | A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. *Journal of Chromatographic Science*, **2008**, 46, 524-8 | 1.4 | 36 |
| 101 | Accelerated oral nanomedicine discovery from miniaturized screening to clinical production exemplified by paediatric HIV nanotherapies. *Nature Communications*, **2016**, 7, 13184 | 17.4 | 35 |
| 100 | Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. *Pharmacogenetics and Genomics*, **2012**, 22, 10-9 | 1.9 | 35 |
| 99 | Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. *Aids*, **2012**, 26, 1529-33 | 3.5 | 33 |
| 98 | Correlates of efavirenz exposure in Chilean patients affected with human immunodeficiency virus reveals a novel association with a polymorphism in the constitutive androstane receptor. *Therapeutic Drug Monitoring*, **2013**, 35, 78-83 | 3.2 | 32 |
| 97 | Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. *Clinical Pharmacokinetics*, **2008**, 47, 793-805 | 6.2 | 31 |
| 96 | Repository Describing an Aging Population to Inform Physiologically Based Pharmacokinetic Models Considering Anatomical, Physiological, and Biological Age-Dependent Changes. *Clinical Pharmacokinetics*, **2019**, 58, 483-501 | 6.2 | 31 |
| 95 | Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. *Therapeutic Drug Monitoring*, **2012**, 34, 722-8 | 3.2 | 30 |
| 94 | Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. *British Journal of Clinical Pharmacology*, **2012**, 74, 134-40 | 3.8 | 29 |
| 93 | Intrapatient and interpatient pharmacokinetic variability of raltegravir in the clinical setting. *Therapeutic Drug Monitoring*, **2012**, 34, 232-5 | 3.2 | 29 |
| 92 | Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro. *Molecular Pharmaceutics*, **2018**, 15, 4835-4842 | 5.6 | 29 |

| | | | |
|---|---|---|---|
| 91 | Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs. *Nanoscale*, **2017**, 9, 6302-6314 | 7.7 | 28 |
| 90 | Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 555-61 | 5.1 | 28 |
| 89 | Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling. *Journal of Infectious Diseases*, **2019**, 219, 1735-1742 | 7 | 26 |
| 88 | Breast milk pharmacokinetics of efavirenz and breastfed infants'exposure in genetically defined subgroups of mother-infant pairs: an observational study. *Clinical Infectious Diseases*, **2015**, 61, 453-63 | 11.6 | 25 |
| 87 | Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. *Hepatology*, **2011**, 54, 2278-9 | 11.2 | 25 |
| 86 | Pharmacokinetics of lamivudine and lamivudine-triphosphate after administration of 300 milligrams and 150 milligrams once daily to healthy volunteers: results of the ENCORE 2 study. *Antimicrobial Agents and Chemotherapy*, **2012**, 56, 1427-33 | 5.9 | 25 |
| 85 | Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. *In Silico Pharmacology*, **2013**, 1, 4 | 4.3 | 24 |
| 84 | Rilpivirine inhibits drug transporters ABCB1, SLC22A1, and SLC22A2 in vitro. *Antimicrobial Agents and Chemotherapy*, **2013**, 57, 5612-8 | 5.9 | 23 |
| 83 | Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. *Aids*, **2006**, 20, 1977-9 | 3.5 | 23 |
| 82 | Long-acting drugs and formulations for the treatment and prevention of HIV infection. *International Journal of Antimicrobial Agents*, **2021**, 57, 106220 | 14.3 | 23 |
| 81 | Once daily maraviroc 300 mg or 150 mg in combination with ritonavir-boosted darunavir 800/100 mg. *Journal of Antimicrobial Chemotherapy*, **2012**, 67, 671-4 | 5.1 | 22 |
| 80 | A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2007**, 848, 374-8 | 3.2 | 22 |
| 79 | CYP3A4*22 (c.522-191 C>T; rs35599367) is associated with lopinavir pharmacokinetics in HIV-positive adults. *Pharmacogenetics and Genomics*, **2014**, 24, 459-63 | 1.9 | 21 |
| 78 | Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies. *Nature Communications*, **2019**, 10, 1413 | 17.4 | 19 |
| 77 | In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents. *Clinical Pharmacokinetics*, **2018**, 57, 255-266 | 6.2 | 19 |
| 76 | Predicting intestinal absorption of raltegravir using a population-based ADME simulation. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 1627-34 | 5.1 | 19 |
| 75 | Nanomedicines for HIV therapy. *Therapeutic Delivery*, **2013**, 4, 153-6 | 3.8 | 19 |
| 74 | A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. *Therapeutic Drug Monitoring*, **2010**, 32, 86-92 | 3.2 | 19 |

| | | | |
|---|---|---|---|
| 73 | Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 144, 101-109 | 5.7 | 18 |
| 72 | Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. *Journal of Antimicrobial Chemotherapy*, **2013**, 68, 907-10 | 5.1 | 18 |
| 71 | Ceftriaxone bone penetration in patients with septic non-union of the tibia. *International Journal of Infectious Diseases*, **2011**, 15, e415-21 | 10.5 | 18 |
| 70 | Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. *Frontiers in Pharmacology*, **2015**, 6, 78 | 5.6 | 17 |
| 69 | Towards a Maraviroc long-acting injectable nanoformulation. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 138, 92-98 | 5.7 | 17 |
| 68 | Improving maraviroc oral bioavailability by formation of solid drug nanoparticles. *European Journal of Pharmaceutics and Biopharmaceutics*, **2019**, 138, 30-36 | 5.7 | 16 |
| 67 | Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 3417-3424 | 5.1 | 16 |
| 66 | Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 2816-22 | 5.1 | 15 |
| 65 | Efavirenz Is Predicted To Accumulate in Brain Tissue: an In Silico, In Vitro, and In Vivo Investigation. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, | 5.9 | 15 |
| 64 | Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes. *Clinical Pharmacokinetics*, **2017**, 56, 409-420 | 6.2 | 15 |
| 63 | Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1066-71 | 5.9 | 15 |
| 62 | Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. *Drugs in R and D*, **2021**, 21, 9-27 | 3.4 | 15 |
| 61 | Physiologically Based Pharmacokinetic Modelling to Identify Pharmacokinetic Parameters Driving Drug Exposure Changes in the Elderly. *Clinical Pharmacokinetics*, **2020**, 59, 383-401 | 6.2 | 15 |
| 60 | Augmented Inhibition of CYP3A4 in Human Primary Hepatocytes by Ritonavir Solid Drug Nanoparticles. *Molecular Pharmaceutics*, **2015**, 12, 3556-68 | 5.6 | 14 |
| 59 | A comprehensive framework for physiologically based pharmacokinetic modelling in Matlab. *CPT: Pharmacometrics and Systems Pharmacology*, **2019**, 8, 444 | 4.5 | 14 |
| 58 | Towards a rational design of solid drug nanoparticles with optimised pharmacological properties. *Journal of Interdisciplinary Nanomedicine*, **2016**, 1, 110-123 | 4 | 13 |
| 57 | Raltegravir penetration in seminal plasma of healthy volunteers. *Antimicrobial Agents and Chemotherapy*, **2010**, 54, 2744-5 | 5.9 | 13 |
| 56 | Efavirenz in an obese HIV-infected patient--a report and an in vitro-in vivo extrapolation model indicate risk of underdosing. *Antiviral Therapy*, **2012**, 17, 1381-4 | 1.6 | 13 |

| | | | |
|---|---|---|---|
| 55 | Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART. *Journal of Antimicrobial Chemotherapy*, **2018**, 73, 1004-1012 | 5.1 | 12 |
| 54 | Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies. *Expert Opinion on Drug Metabolism and Toxicology*, **2015**, 11, 1203-17 | 5.5 | 11 |
| 53 | Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications. *Antimicrobial Agents and Chemotherapy*, **2018**, 62, | 5.9 | 11 |
| 52 | The Application of Nanotechnology to Drug Delivery in Medicine **2015**, 173-223 | | 11 |
| 51 | Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs. *Journal of Antimicrobial Chemotherapy*, **2017**, 72, 805-811 | 5.1 | 11 |
| 50 | Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, | 5.9 | 10 |
| 49 | Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies. *European Journal of Pharmaceutical Sciences*, **2019**, 140, 105068 | 5.1 | 10 |
| 48 | Class-specific relative genetic contribution for key antiretroviral drugs. *Journal of Antimicrobial Chemotherapy*, **2015**, 70, 3074-9 | 5.1 | 10 |
| 47 | Misoprostol-induced fever and genetic polymorphisms in drug transporters SLCO1B1 and ABCC4 in women of Latin American and European ancestry. *Pharmacogenomics*, **2015**, 16, 919-28 | 2.6 | 10 |
| 46 | CYP2B6 516G>T (rs3745274) and smoking status are associated with efavirenz plasma concentration in a Serbian cohort of HIV patients. *Therapeutic Drug Monitoring*, **2014**, 36, 734-8 | 3.2 | 10 |
| 45 | Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults. *Aids*, **2015**, 29, 193-200 | 3.5 | 9 |
| 44 | Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. *Antiviral Therapy*, **2011**, 16, 499-504 | 1.6 | 9 |
| 43 | Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. *Journal of Antimicrobial Chemotherapy*, **2009**, 64, 874-5 | 5.1 | 9 |
| 42 | A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. *Therapeutic Drug Monitoring*, **2008**, 30, 90-4 | 3.2 | 9 |
| 41 | Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. *Clinical Infectious Diseases*, **2007**, 45, 1654-5 | 11.6 | 9 |
| 40 | Flow cytometric analysis of the physical and protein-binding characteristics of solid drug nanoparticle suspensions. *Nanomedicine*, **2015**, 10, 1407-21 | 5.6 | 8 |
| 39 | Derivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approach. *Drug Metabolism and Pharmacokinetics*, **2018**, 33, 179-187 | 2.2 | 8 |
| 38 | Physiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspective. *Future Virology*, **2013**, 8, 871-890 | 2.4 | 8 |

| | | | |
|---|---|---|---|
| 37 | Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 640-647 | 5.1 | 8 |
| 36 | Incompatibility of chemical protein synthesis inhibitors with accurate measurement of extended protein degradation rates. *Pharmacology Research and Perspectives*, **2017**, 5, e00359 | 3.1 | 7 |
| 35 | Development, validation and utilization of a highly sensitive LC-MS/MS method for quantification of levonorgestrel released from a subdermal implant in human plasma. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2018**, 1084, 106-112 | 3.2 | 7 |
| 34 | Effect of Pregnancy on the Pharmacokinetic Interaction between Efavirenz and Lumefantrine in HIV-Malaria Coinfection. *Antimicrobial Agents and Chemotherapy*, **2018**, 62, | 5.9 | 7 |
| 33 | Physiologically-based pharmacokinetic modelling of infant exposure to efavirenz through breastfeeding. *AAS Open Research*,1, 16 | 1.8 | 7 |
| 32 | Effect of ageing on antiretroviral drug pharmacokinetics using clinical data combined with modelling and simulation. *British Journal of Clinical Pharmacology*, **2021**, 87, 458-470 | 3.8 | 7 |
| 31 | Physiologically-Based Pharmacokinetic Modeling for Optimal Dosage Prediction of Quinine Coadministered With Ritonavir-Boosted Lopinavir. *Clinical Pharmacology and Therapeutics*, **2020**, 107, 1209-1220 | 6.1 | 6 |
| 30 | Effect of patient genetics on etonogestrel pharmacokinetics when combined with efavirenz or nevirapine ART. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 3003-3010 | 5.1 | 5 |
| 29 | Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate. *Antimicrobial Agents and Chemotherapy*, **2017**, 61, | 5.9 | 5 |
| 28 | Prophylactic drug monitoring of itraconazole in an oncohematological pediatric patient population. *Therapeutic Drug Monitoring*, **2012**, 34, 604-6 | 3.2 | 5 |
| 27 | A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivo. *European Journal of Nanomedicine*, **2017**, 9, | | 4 |
| 26 | Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling. *Antimicrobial Agents and Chemotherapy*, **2020**, 64, | 5.9 | 4 |
| 25 | Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 1041-5 | 5.1 | 4 |
| 24 | Towards a computational prediction of nanoparticle pharmacokinetics and distribution **2016**, 02, | | 4 |
| 23 | Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations. *Nanoscale Advances*, **2019**, 1, 4301-4307 | 5.1 | 4 |
| 22 | Clinical Data Combined With Modeling and Simulation Indicate Unchanged Drug-Drug Interaction Magnitudes in the Elderly. *Clinical Pharmacology and Therapeutics*, **2021**, 109, 471-484 | 6.1 | 4 |
| 21 | The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation. *Advanced Drug Delivery Reviews*, **2018**, 131, 116-121 | 18.5 | 4 |
| 20 | Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. *Journal of the International AIDS Society*, **2014**, 17, 19586 | 5.4 | 3 |

| | | | |
|---|---|---|---|
| 19 | The Current Landscape of Novel Formulations and the Role of Mathematical Modeling in Their Development. *Journal of Clinical Pharmacology*, **2020**, 60 Suppl 1, S77-S97 | 2.9 | 3 |
| 18 | Mechanisms of Drug Interactions II: Transport Proteins **2018**, 49-85 | | 2 |
| 17 | Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine. *Clinical Pharmacokinetics*, **2015**, 54, 107-16 | 6.2 | 2 |
| 16 | A multisystem investigation of raltegravir association with intestinal tissue: implications for pre-exposure prophylaxis and eradication. *Journal of Antimicrobial Chemotherapy*, **2014**, 69, 3275-81 | 5.1 | 2 |
| 15 | Validation of Computational Approaches for Antiretroviral Dose Optimization. *Antimicrobial Agents and Chemotherapy*, **2016**, 60, 3838-9 | 5.9 | 2 |
| 14 | Integrated pharmacokinetic modelling for accelerated nanomedicine translation. *European Journal of Nanomedicine*, **2017**, 9, 1-3 | | 1 |
| 13 | The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics. *Journal of Antimicrobial Chemotherapy*, **2020**, 75, 2381-2383 | 5.1 | 1 |
| 12 | Physiologically based pharmacokinetic modeling for dose optimization of quinine-phenobarbital coadministration in patients with cerebral malaria. *CPT: Pharmacometrics and Systems Pharmacology*, **2021**, 11, 104 | 4.5 | 1 |
| 11 | Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling. *Clinical Pharmacokinetics*, **2021**, 1 | 6.2 | 1 |
| 10 | Influence of selected polymorphisms in disposition genes on lumefantrine pharmacokinetics when coadministered with efavirenz. *Pharmacogenetics and Genomics*, **2020**, 30, 96-106 | 1.9 | 1 |
| 9 | Development and validation of an LC-MS/MS assay for the quantification of efavirenz in different biological matrices. *Bioanalysis*, **2016**, 8, 2125-34 | 2.1 | 1 |
| 8 | Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics. *Pharmacogenomics*, **2019**, 20, 217-223 | 2.6 | 1 |
| 7 | PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease.. *Frontiers in Pharmacology*, **2022**, 13, 814134 | 5.6 | 0 |
| 6 | A physiologically based pharmacokinetic model to predict pegylated liposomal doxorubicin disposition in rats and human.. *Drug Delivery and Translational Research*, **2022**, 1 | 6.2 | 0 |
| 5 | In vitro characterisation of solid drug nanoparticle compositions of efavirenz in a brain endothelium cell line. *Journal of Interdisciplinary Nanomedicine*, **2017**, 2, 157-169 | 4 | |
| 4 | Prediction and optimization of photo-activated curcumin dosage schedule in human, a promising antimicrobial candidate: A physiologically-based pharmacokinetic (PBPK) modeling. *Proceedings for Annual Meeting of the Japanese Pharmacological Society*, **2018**, WCP2018, PO1-11-30 | 0 | |
| 3 | Development of Prodrug Approaches for Long-Acting Nanoformulations of Emtricitabine-Based Regimens. *FASEB Journal*, **2018**, 32, 828.3 | 0.9 | |
| 2 | Computational Predictive Models for Nanomedicine **2016**, 379-402 | | |

# LIST OF PUBLICATIONS

1    In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel.
     *HIV Medicine*, **2021**, 22, 898-906                                                    2.7